期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

钠-葡萄糖协同转运蛋白2抑制剂治疗糖尿病研究新进展 被引量：5

Latest research progress on treatment with sodium-glucose cotransporter 2inhibitors in diabetes mellitus
原文传递
导出
摘要 钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂通过抑制SGLT2促进肾脏排出葡萄糖以改善血糖水平。与其他口服降糖药或胰岛素联用可增加降糖效果。还可通过尿液排出过多卡路里以减轻体重,为糖尿病患者提供更好的治疗效果。随着病情进展,糖尿病患者肾小球滤过功能降低,SGLT2抑制剂可能有肾脏保护作用。 The mechanism of action of sodium-glucose cotransporter 2 （SGLT2） inhibitors is that SGLT2 inhibitors can modulate renal glucose reabsorption and plasma glucose level. They can combinedly be used with other oral antidiabetic drugs or insulin with better hypoglycemic effects. Weight loss owing to urinary calorie leakage and the negative energy balance offer a valuable clinical benefit. Through reducing glomerular filtration rate, SGLT2 inhibitors may decrease the progression of the disease and play a renal protective role.
作者 刘锴 宋海燕
机构地区 哈尔滨医科大学附属第二医院内分泌代谢病科
出处 《中国糖尿病杂志》 CAS CSCD 北大核心 2014年第3期280-282,共3页 Chinese Journal of Diabetes
关键词 糖尿病 钠-葡萄糖协同转运蛋白2 钠-葡萄糖协同转运蛋白2抑制剂 Diabetes mellitus Sodium-glucose cotransporter 2 （SGLT2.） Sodium-glucosecotransporter 2 inhibitors
分类号 R587.1 [医药卫生—内分泌]
  • 相关文献

参考文献17

  • 1Wright EM, Loo DD, Hirayama BA. Biology of human sodiumglucose transporters. Physiol Rev, 2011,91: 733-794.
  • 2Hummel CS, Lu C, Loo DD, et al. Glucose transport by hu-man renal Na+ /D- glucose cotransporters SGLT1 andSGLT2. Am J Physiol Cell Physiol, 2011, 300:C14-C21.
  • 3Lee YJ, Kim MO, Ryu JM, et al. Regulation of SGLT expres-sion and localization through Epac/PKA-dependent caveolin-1and F-actin activation in renal proximal tubule cells. BiochimBiophys Acta, 2012, 1823:971-982.
  • 4Nair S,Wilding JP. Sodium glucose cotransporter 2 inhibitorsas a new treatment for diabetes mellitus. J Clin EndocrinolMetab, 2010,95:34-42.
  • 5Maurer TS,Ghosh A, Haddish-Berhane N, et al. Pharmaco-dynamic model of sodium-glucose transporter 2(SGLT2) inhibi-tion: implications for quantitative translational pharmacology.AAPSJ, 2011,13:576-584.
  • 6Raskin P. Sodium-glucose cotransporter inhibition: therapeuticpotential for the treatment of type 2 diabetes mellitus. EHabetesMetab Res Rev, 2013,29:347-356.
  • 7Fujimori Y, Katsuno K, Ojima K, et al. Sergliflozin etabonate, aselective SGLT2 inhibitor. improves ^ycemic control in streptozo-tocin-induced diabetic rats and Zucker fatty rats. Eur J Pharmacol,2009, 609:148-154.
  • 8Fujimori Y, Katsuno K, Nakashima I, et al. Remogliflozineta-bonate, in a novel category of selective low-affinity sodium glu-cose cotransporter (SGLT2) inhibitors, exhibits antidiabeticefficacy in rodent models. J Pharmacol Exp Ther,2008, 327:268-276.
  • 9Grempler R,Thomas L,Eckhardt M, et al. Empagliflozin, anovel selective sodium glucosecotransporter-2 (SGLT-2) inhibi-tor: characterizationand comparison with other SGLT-2 inhibi-tors. Diabetes Obes Metab, 2012,14:83-90.
  • 10Luippold G,Klein T,Mark M,et al. Empagliflozin, a novelpotent and selective SGLT-2 inhibitor, improves glycaemic con-trol alone and in combination with insulin in streptozotocin-in-duced diabetic rats,a model of type 1 diabetes mellitus. Diabe-tes Obes Metab, 2012, 14:601-607.

同被引文献54

  • 1Davis SN. Canagliflozin versus glimepiride treatment in patients with type 2 diabetes inadequately controlled with metformin(CANTATA-SU trial)[J]. Expert Rev Clin Pharmacol, 2014, 7(I): 21-23.
  • 2Ridderstrale M, Svaerd R, Zeller C, et al. Rationale, design and baseline characteristics of a 4-year(208-week)phase 111 trial of empagliflozin, an SGLT-2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mcllitus with insufficient glycemic control[J]. Cardiovasc Diabetol, 2013, 12: 129.
  • 3Scheen AJ. Evaluating SGLT-2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations[J]. Expert Opin Drug Metab Toxicol, 2014, 10(5): 647-663.
  • 4Doggrell SA, Mclntyre K. Canagliflozin-something new for type 2 diabetes, but is it safe and efficacious[J]? Expert Opin Pharmacother, 2014, 15(3): 437-441.
  • 5Nicolle LE, Capuano G, Fung A, et al. Urinary tract infection in randomized phase 111 studies of canagliflozin, a sodium glucose co- transporter 2 inhibitor[J]. Postgrad Med, 2014, 126(1): 7-17.
  • 6Nicolle LE, Capuano G, Ways K, et al. Effect of canagliflozin, a sodium glucose co-transporter 2(SGLT-2)inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study[J]. Curt Med Res Opin, 2012, 28(7): 1167-1171.
  • 7Sinclair A, Bode B, Harris S, et al. Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies[J]. BMC Endocr Disord, 2014, 14: 37.
  • 8Lavalle-Gonzalez F J, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial[J]. Diabetologia, 2013, 56(12): 2582-2592.
  • 9Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin(CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial[J]. Lancet, 2013, 382(9896): 941-950.
  • 10Neal B, Perkovic V, de Zeeuw D, et aI. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study(CANVAS)--a randomized placebo-controlled trial[J]. Am Heart J, 2013, 166(2): 217-223.

引证文献5

二级引证文献41

中国糖尿病杂志
2014年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部